Ricerca avanzata

Home > Riviste > Minerva Urologica e Nefrologica > Fascicoli precedenti > Articoli online first > Minerva Urologica e Nefrologica 2016 Oct 21

FASCICOLI E ARTICOLI   I PIÙ LETTI   eTOC

ULTIMO FASCICOLOMINERVA UROLOGICA E NEFROLOGICA

Rivista di Nefrologia e Urologia

Indexed/Abstracted in: EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 0,536

Periodicità: Bimestrale

ISSN 0393-2249

Online ISSN 1827-1758

 

Minerva Urologica e Nefrologica 2016 Oct 21

Our experience in the treatment of vertebral metastases from renal cell carcinoma: a retrospective study

Giulia R. MOSELE 1, Gianfilippo CAGGIARI 1, Roberto M. SCARPA 2, Carlo DORIA 1

1 Orthopaedic Department, University of Sassari, Sassari, Italy; 2 Department of Oncology, University of Turin, Turin, Italy

BACKGROUND: Renal cell carcinoma (RCC) is among the 10 most common cancers in both men and women. It comprises 2-3% of all malignancies. The most common site for metastasis from RCC is the lung (50% of patients), followed by the skeleton (20% to 50% of patients).
METHODS: We retrospectively reviewed our consecutive series of 63 patients surgically treated for spinal metastases from RCC. The surgical treatment for spinal metastases varied in each patient. Factors influencing the choice of surgery included age, disease status, symptoms, morbidity of the patient, the location, the number of repetitive lesions and the existence of extra-osseous metastases. For 42 patients (66.66%) the treatment included radiation two weeks after the surgical procedure.
RESULTS: A total of 68 surgical procedures were performed in 63 patients. For all patients we collected data about type of RCC, locations of metastasis, type of spine metastasis, type of surgery and complications. In this way we had an exahustive vision of the natural historyof this kind of patients.
CONCLUSIONS: Spine metastatic RCC has a poor prognosis. The favorable prognostic factor is solitary spinal metastasis without involvement of visceral organs where the gold standard treatment fractures and neurological deficits. Bisphosphonate as zoledronic acid reduce significantly skeletal morbidity and significantly prolong time to bone lesion progression in patients with spine metastases from renal cell carcinoma.

lingua: Inglese


FULL TEXT  ESTRATTI

inizio pagina